Integumen PLC Issue of Equity: Shares in Lieu of Invoice (1674P)
October 08 2019 - 7:34AM
UK Regulatory
TIDMSKIN
RNS Number : 1674P
Integumen PLC
08 October 2019
AIM share code: SKIN
8 October 2019
Integumen PLC
("Integumen" or "Company")
Issue of Equity : Shares in Lieu of Invoice
Integumen announces that it has been requested to issue
1,176,471 ordinary shares of 0.01p in the share capital of
Integumen in exchange for amounts due under an invoice from one of
the Company's service providers dated 16 September 2019 ("the
Invoice Shares"). The consideration for the Invoice Shares amounts,
in aggregate, to a cash value of GBP20,000.
At a board meeting held today, 1,176,471 shares have been
allotted. Application has today been for these shares to be
admitted to trading on AIM, and such Admission is expected on or
around 14 October 2019.
Total voting rights
The Company's total issued share capital, following the issue of
the Invoice Shares, will be 981,163,373 ordinary shares. As the
Company does not hold any shares in Treasury, this figure may be
used by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company following Admission.
Integumen plc Gerard Brandon, CEO +44 (0) 7340 055 648
SPARK Advisory Partners
Limited
(Nominated Adviser) Neil Baldwin +44 (0) 113 370 8974
--------------------- ---------------------
Turner Pope Investments Andy Thacker/Zoe
(TPI) Limited (Broker) Alexander +44 (0) 20 3621 4120
--------------------- ---------------------
About Integumen:
Integumen is a vertically integrated product and services
company for skin related diseases, treatments and therapies with
three business units:
-- Labskin AI's technology platform incorporates artificial
intelligence within clinical research for medical device,
pharmaceuticals, cosmeceuticals and related life science test
services. Labskin allows skincare, healthcare, pharmaceutical
manufacturers and cosmetic companies to test their products on
human-like skin in a real-world environment with full access to
multiple state-of-the-art partner technologies.
-- Wound pHase is developing skin and wound care products using
its proprietary wound dressing technology. Working in collaboration
with CBD providers creating a CBD infused diabetic wound care
product range.
Stoer-for-men skin products e-commerce division offers a range
of skincare products derived from 5 natural super-ingredient plant
extracts specifically for men to reduce the signs of ageing and is
also used as a control for client testing within Labskin
laboratories.
The Company combines data analytics with access to therapeutic
operational expertise and offers solutions to our clients, from
regulatory approvals, right through to marketing fully tested
ingredients that have been certified on our Laboratory grown living
human tissue.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEBBBDGBXGBGCI
(END) Dow Jones Newswires
October 08, 2019 07:34 ET (11:34 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Apr 2024 to May 2024
Integumen (LSE:SKIN)
Historical Stock Chart
From May 2023 to May 2024